ELL and acute myeloid leukemia: In the 2022 WHO classification, AML with KMT2A rearrangement replaces “AML with t(9;11)(p22;q23); KMT2A-MLLT3”, because over 80 KMT2A fusion partners have been described, with MLLT3, AFDN, ELL, and MLLT10 being most common.